NeoGenomics Inc (NEO)
8.685
+0.30 (+3.52%)
USD |
NASDAQ |
May 19, 15:55
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 1.084B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -77.72% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 2.234 |
Price to Book Value | 1.008 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.496 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 84.22% |
News
Headline
Wire
Time (ET)
Accesswire
05/10 02:00
Yahoo
05/09 07:00
Yahoo
05/05 06:53
Globe Newswire
05/01 21:00
MT Newswires
04/28 14:30
MT Newswires
04/28 12:37
Events
DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
08/05/2022* | -- | Results | Q2 2022 | -- | -0.22 | -- | |
08/05/2022* | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
04/27/2022 | -- | Results | Q1 2022 | -- | -0.24 | -- | |
04/27/2022 | 08:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
02/23/2022 | -- | Results | Q4 2021 | -0.14 | -0.15 | 3.75% | |
02/23/2022 | 08:30 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
11/04/2021 | -- | Results | Q3 2021 | -0.08 | -0.09 | 6.79% | |
11/04/2021 | 08:30 EST | Earnings Call | Q3 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services. |
URL | https://www.neogenomics.com |
Investor Relations URL | https://ir.neogenomics.com/ |
HQ State/Province | Florida |
Sector | Healthcare |
Industry | Diagnostics & Research |
Equity Style | Small Cap/Blend |
Next Earnings Release | Aug. 05, 2022 (est.) |
Last Earnings Release | Apr. 27, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Dividends
Dividend Per Share (TTM) | -- |
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
Yield to Market | 0.00 |
Yield to Sector | 0.00 |
Yield to Industry | 0.00 |
Last Dividend Amt. | -- |
Dividend Frequency | -- |
Last Ex-Dividend Date | -- |
Yield (TTM) | 0% |
Forward Yield | -- |
Payout Ratio | 0.00% |
Cash Payout Ratio | 0.00% |
Consistent Payer (5Y) | No |
Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of May 18, 2022.
Fundamentals
Revenue (TTM) | 485.96M |
Total Expenses (TTM) | 641.64M |
Net Income (TTM) | -35.64M |
Total Assets (Quarterly) | 1.830B |
Total Liabilities (Quarterly) | 754.54M |
Shareholders Equity (Quarterly) | 1.075B |
Cash from Operations (TTM) | -57.97M |
Cash from Investing (TTM) | -465.63M |
Cash from Financing (TTM) | 206.41M |
Ratings
Profile
Edit
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services. |
URL | https://www.neogenomics.com |
Investor Relations URL | https://ir.neogenomics.com/ |
HQ State/Province | Florida |
Sector | Healthcare |
Industry | Diagnostics & Research |
Equity Style | Small Cap/Blend |
Next Earnings Release | Aug. 05, 2022 (est.) |
Last Earnings Release | Apr. 27, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Risk Info
Ownership
Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Other Resources
Whale Wisdom | 13F Filings |
Seeking Alpha | Call Transcripts |
Morningstar | Insider Trading |
Nasdaq | Institutional Ownership |
Nasdaq | Option Chain |
SEC | SEC Filings |
NEO Tweets |